Editorial: Dissecting malaria protective immunity: acquired by natural infection and/or vaccination

Malaria remains a major global health challenge. Although the WHO has recommended both RTS,S/AS01 (Asante et al., 2024) and R21/Matrix-M (Datoo et al., 2024) vaccines, their protection is modest and short-lived, reflecting gaps in our understanding of the mechanisms that drive durable immunity. Next-generation malaria vaccines will need to provide stronger, longerlasting protection, target multiple parasite stages, remain scalable and affordable, and complement existing control strategies. This Research Topic provides a platform to highlight studies on protective immunity against P. falciparum and P. vivax malaria acquired through natural infection or vaccination. The contributions collectively address three interrelated questions: (i) what immune mechanisms are associated with protection; (ii) how exposure history, age, and physiological state shape immune regulation; and (iii) how these insights can be leveraged to design next-generation malaria vaccines.Antibodies targeting P. falciparum proteins are important for malaria immunity by blocking invasion of liver and red blood cells, preventing sequestration of infected erythrocytes (IEs), facilitating IEs clearance, and reducing transmission (Stanisic and McCall, 2021) (2025) used surface plasmon resonance to show that antibody affinity for two merozoite antigens, AMA1 and MSP2, matures gradually over the first nine months of life. In contrast, affinity for CSP remained low and stable throughout the study period, suggesting that structural characteristics of CSP may inherently limit the induction of high-affinity antibody responses during natural infection. This decoupling of quantity and quality underscores the limitations of antibody titre-based correlates of protection and highlights affinity maturation as a critical, antigen-specific bottleneck in the development of natural immunity.In the case of P. vivax, Soares et al. ( 2026) found that naturally acquired anti-PvRipr IgG and IgM responses were detected in individuals exposed to malaria in the Brazilian Amazon. The findings are noteworthy given that the orthologous Ripr antigen in P. falciparum is currently in preclinical (Nagaoka et al., 2026) (Takashima et al., 2022) and clinical phases (ClinicalTrials.gov: NCT07183371).Structural determinants also play a role in the immune system's recognition of polymorphic antigens. Zerebinski et al. ( 2024) demonstrated that naturally acquired IgG responses against MSP2 primarily target the highly polymorphic variable regions rather than the conserved termini. Alphafold3 modeling predicted extensive structural heterogeneity and epitope masking in the conserved termini upon antigen oligomerization, which likely serves as a parasite evasion mechanism.Pfs230D1M and Pfs48/45 are prevalent, stable, and age-associated in Tanzanian populations.Transmission-reducing activity was detectable in individuals who were highly reactive to Pfs230D1M and Pfs48/45, indicating that antibody responses were functional. These findings suggest that naturally primed populations may be well suited for boosting transmission-blocking immunity, with direct implications for vaccine deployment strategies.To overcome the limitations of current vaccines, research is also shifting toward multi-stage This Research Topic collectively demonstrates that durable malaria protection stems from coordinated humoral, cellular, and regulatory immune networks rather than antibody magnitude alone. Next-generation vaccines will require multi-stage, multivalent designs and strategies that enhance antibody quality/long-term memory, and systems-level integration to achieve sustainable, population-wide protection.